benefit-risk profile for Hydroxychloroquine in the COVID-19 treatment

An unfavourable benefit-risk profile for Hydroxychloroquine in the COVID-19 treatment

Hydroxychloroquine is an antimalarial class of drug which is used in the treatment and prevention of acute attacks of malaria. It is also used to treat discoid or systemic lupus erythematosus, rheumatic disorders like rheumatoid arthritis, porphyria cutanea tarda and Q fever. Hydroxychloroquine acts by increasing pH within intracellular vacuoles and alter processes such as protein

COVID-19 Medicine Update

COVID-19 Medicine Update: Restricted Emergency Use authorizations (EUA) for Medications in India

The national regulatory body for Indian pharmaceuticals and medical devices- Central Drugs Standard Control Organisation (CDSCO) has provided approval as part of restricted & emergency use authorization for the below two medicines considering the unmet medical need for treatment of COVID-19 infected patients- Favipiravir Tablets for mild to moderate COVID-19 infection subject to various conditions

Highlights of Remdesivir (A potential treatment for COVID-19?)

Remdesivir (GS-5734) is being developed by Gilead Sciences, an American biopharmaceutical company based in California with a primary therapeutic focus in antiviral medicines. Remdesivir is an antiviral drug (broad spectrum) under clinical trial investigation for the treatment of COVID-19 (coronavirus disease). Remdesivir gained public attention due to publication of some of its clinical study results

USFDA’s Drug Safety Communication: Caution on COVID-19 medication

Food and Drug Administration (FDA) in the United States announced a serious safety concern on the use of hydroxychloroquine or chloroquine for the treatment of 2019 Coronavirus Disease (COVID-19) due to abnormal heart rhythms like QT prolongation and ventricular tachycardia. Currently, there are no medicines proven effective for the treatment of COVID-19. On 28‑Mar‑2020, FDA released

error: Content is protected !!